Aimmune Therapeutics (AIMT) Tops Q1 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aimmune Therapeutics (AIMT) Tops Q1 EPS by 15c

Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights

May 11, 2020 4:05 PM EDT

Continues to be launch ready for PALFORZIATM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply for all ongoing clinical trials $371.6 million cash, cash equivalents and investments on-hand and implementing numerous cash-preservation measures Webcast and conference call today at 4:30 p.m. ET 

 

BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for... More